{"pmid":32480248,"pmcid":"PMC7251351","title":"Is there enough evidence to discontinue the renin-angiotensin system inhibitors in patients with COVID-19?","text":["Is there enough evidence to discontinue the renin-angiotensin system inhibitors in patients with COVID-19?","Med Hypotheses","Bobkova, Irina","Kamyshova, Elena","Rudenko, Tatiana","Stavrovskaya, Ekaterina","Moiseev, Sergey","32480248"],"journal":"Med Hypotheses","authors":["Bobkova, Irina","Kamyshova, Elena","Rudenko, Tatiana","Stavrovskaya, Ekaterina","Moiseev, Sergey"],"date":"2020-06-02T11:00:00Z","year":2020,"_id":"32480248","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1016/j.mehy.2020.109888","topics":["Treatment","Mechanism"],"weight":1,"_version_":1668532089557876736,"score":9.490897,"similar":[{"pmid":32436403,"title":"Evidence that Renin-Angiotensin System Inhibitors Should not be Discontinued Due to the COVID-19 Pandemic.","text":["Evidence that Renin-Angiotensin System Inhibitors Should not be Discontinued Due to the COVID-19 Pandemic.","Hypertension","Carey, Robert M","Wang, Ji-Guang","32436403"],"journal":"Hypertension","authors":["Carey, Robert M","Wang, Ji-Guang"],"date":"2020-05-22T11:00:00Z","year":2020,"_id":"32436403","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1161/HYPERTENSIONAHA.120.15263","keywords":["covid-19"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1667521393528406016,"score":88.01211},{"pmid":32409434,"title":"Renin-angiotensin system inhibitors in COVID-19.","text":["Renin-angiotensin system inhibitors in COVID-19.","Concerns have been raised about the potential for renin-angiotensin system (RAS) inhibitors to upregulate expression of angiotensin-converting enzyme 2 (ACE2) and thus increase susceptibility to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) entry. Currently, there is no evidence that even if RAS inhibitors increase expression and activity of ACE2, that they would increase the risk of SARS-CoV-2 infection by facilitating greater viral entry or worsen outcomes in patients with COVID-19. At this time, there is no clinical evidence to suggest that treatment with RAS inhibitors should be discontinued in stable patients with COVID-19. In hospitalized patients with severe COVID-19, decisions about these medications should be based on clinical condition, including hemodynamic status and renal function.","Cleve Clin J Med","Thomas, George","32409434"],"abstract":["Concerns have been raised about the potential for renin-angiotensin system (RAS) inhibitors to upregulate expression of angiotensin-converting enzyme 2 (ACE2) and thus increase susceptibility to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) entry. Currently, there is no evidence that even if RAS inhibitors increase expression and activity of ACE2, that they would increase the risk of SARS-CoV-2 infection by facilitating greater viral entry or worsen outcomes in patients with COVID-19. At this time, there is no clinical evidence to suggest that treatment with RAS inhibitors should be discontinued in stable patients with COVID-19. In hospitalized patients with severe COVID-19, decisions about these medications should be based on clinical condition, including hemodynamic status and renal function."],"journal":"Cleve Clin J Med","authors":["Thomas, George"],"date":"2020-05-16T11:00:00Z","year":2020,"_id":"32409434","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.3949/ccjm.87a.ccc009","topics":["Treatment","Mechanism"],"weight":1,"_version_":1666989866099933184,"score":65.458626},{"pmid":32332039,"title":"Renin-angiotensin-aldosterone system inhibitors and COVID-19.","text":["Renin-angiotensin-aldosterone system inhibitors and COVID-19.","CMAJ","Quinn, Kieran L","Fralick, Michael","Zipursky, Jonathan S","Stall, Nathan M","32332039"],"journal":"CMAJ","authors":["Quinn, Kieran L","Fralick, Michael","Zipursky, Jonathan S","Stall, Nathan M"],"date":"2020-04-26T11:00:00Z","year":2020,"_id":"32332039","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.1503/cmaj.200619","e_drugs":["Aldosterone"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666138493934370817,"score":62.768917},{"pmid":32356625,"title":"Inhibitors of the Renin-Angiotensin-Aldosterone System and Covid-19.","text":["Inhibitors of the Renin-Angiotensin-Aldosterone System and Covid-19.","N Engl J Med","Jarcho, John A","Ingelfinger, Julie R","Hamel, Mary Beth","D'Agostino, Ralph B Sr","Harrington, David P","32356625"],"journal":"N Engl J Med","authors":["Jarcho, John A","Ingelfinger, Julie R","Hamel, Mary Beth","D'Agostino, Ralph B Sr","Harrington, David P"],"date":"2020-05-02T11:00:00Z","year":2020,"_id":"32356625","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1056/NEJMe2012924","e_drugs":["Aldosterone"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666138495160156160,"score":62.768917},{"pmid":32427428,"title":"Renin-Angiotensin-Aldosterone System Inhibitors in Covid-19.","text":["Renin-Angiotensin-Aldosterone System Inhibitors in Covid-19.","N Engl J Med","Lubel, John","Garg, Mayur","32427428"],"journal":"N Engl J Med","authors":["Lubel, John","Garg, Mayur"],"date":"2020-05-20T11:00:00Z","year":2020,"_id":"32427428","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1056/NEJMc2013707","link_comment_for":"32227760","e_drugs":["Aldosterone"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1667352728891817985,"score":62.768917}]}